title: Osteonecrosis in patients with testicular tumours treated with chemotherapy.
abstract: The role of antiemetics is invaluable in allowing cancer patients to complete, otherwise possibly intolerable, chemotherapy. In the Perugia Consensus Conference it was decided that the recommended antiemetic regimen in the prevention of acute emesis induced by a single high, low and repeated doses of cisplatin is a serotonin receptor antagonist plus dexamethasone. We describe three testicular cancer patients who were cured with chemotherapy but developed bilateral osteonecrosis of the femoral head 17, 22 and 55 months after chemotherapy. It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients. Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines. Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug. A recommendation to add corticosteroids to serotonin receptor antagonists only after demonstrated nausea in chemotherapy regimes with low-dose cisplatin (20 mg/m2) for five days seems justified.
authors.affiliation: Department of Medical Oncology (550), University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands. f.vandenberkmortel@onco.umcn.nl
authors.forename: F
authors.initials: F
authors.lastname: van den Berkmortel
authors.forename: R
authors.initials: R
authors.lastname: de Wit
authors.forename: J
authors.initials: J
authors.lastname: de Rooy
authors.forename: P
authors.initials: P
authors.lastname: DeMulder
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005271:Femur Head Necrosis / Q000139:chemically induced*; D006801:Humans; D008297:Male; D012307:Risk Factors; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D012702:Serotonin Antagonists; D003907:Dexamethasone